TRIUMEQ国内上市了吗？

Suimeikai () is composed of three ingredients: DTG (DTG) + abacavir (ABC) + lamivudine (3TC). It is a compound treatment of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV drug zidovudine (AZT) in 1987, it has brought life hope to AIDS patients. Subsequently, more and more drugs have continued to appear, with more and more types of drugs, better and better therapeutic effects, and fewer and fewer side effects. At present, the world has basically entered the era of integrase inhibitor drugs, and continues to introduce new ones in the optimization of multi-drug combination regimens.

AIDS is an infectious disease that can be transmitted through sexual contact, blood, and mother-to-child transmission. Currently, there is still a lack of effective drugs to cure HIV infection worldwide. It can only reduce the viral load to the maximum and lasting extent and improve the patient's quality of life.

As a compound preparation, TRIUMEQ can achieve the effect of combined medication by taking one drug. The drug's antiviral effect is similar to that of tenofovir, but it has less damage to mitochondria, thereby reducing fat consumption, pancreatitis, neuritis, lactic acidosis and other adverse reactions. It has the characteristics of high efficacy, good tolerance, high resistance barrier and few drug interactions.

Is TRIUMEQ launched in China?

TRIUMEQ is the best-selling HIV drug in the world in the past five years, and it is also an important player of GSK China in the field of HIV in recent years. Since TRIUMEQ was approved for launch in 2014, its sales have grown by leaps and bounds. In 2016, it ranked first in the global AIDS drug rankings, becoming the best-performing business segment of GSK.

Glaxo submitted a clinical application in China in 2015; applied for import on January 20, 2017, and obtained priority review qualification; and was approved by the CFDA on August 1, 2017. At present, Suimeike () has been approved for marketing in 50 countries and regions, and has been recommended by many European and American academic institutions and guidelines as the first-line treatment of choice for patients with newly diagnosed HIV infection.